ALS TDI and to-BBB collaborate on potential treatments for Motor Neuron Disease
The ALS Therapy Development Institute (ALS TDI) announced that it has entered into a new collaboration with to-BBB to investigate potential treatments for ALS (aka Motor Neuron or Lou Gehrig’s disease).
The blood-brain barrier (BBB) fortifies the walls of blood vessels to prevent the entry of certain toxic substances into the brain. While maintaining this crucial protection, the barrier also poses challenges to delivering potential therapeutics for neurodegenerative disorders such as ALS.
Under the terms of the agreement, ALS TDI will use to-BBB’s CNS-targeted liposomal drug delivery system, the G-Technology®, as a tool to enhance the transport of several different compounds to the brain across the blood-brain barrier. The Institute will screen compounds in a preclinical model of ALS to determine if the enhanced formulation of the proposed treatments have an improved effect on disease course.
Other news from the department research and development
